Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Asciminib in Renal Impairment
NCT03605277Phase 1Completed
- Sponsor
- Novartis
- Start
- Nov 2018
- Primary completion
- Mar 2019
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 1, open-label trial of asciminib in chronic myeloid leukemia (CML) (4 arms), sponsored by Novartis. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration at 72 hours, Area Under the Plasma Concentration-time Curve From Time Zero to Infinity at 72 hours and 2 more. Started Nov 2018; status: completed.
02
Drugs
asciminib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT03605277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03605277.